Evidence map›Paper›PMID 35608608›Full record

SynthesisThe Cochrane database of systematic reviews2022

Medical methods for first trimester abortion.

Jing Zhang, Kunyan Zhou, Dan Shan, Xiaoyan Luo

Open access · greenAbstract readSystematic Review
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Post protocol residual thickness as a negative predictor for pharmacological treatment in early pregnancy loss.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
    Article
  6. Demographic Factors Influencing Eligibility for EMA in South Australia.The Australian & New Zealand journal of obstetrics & gynaecology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Abortion Surveillance - United States, 2022.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2024
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jing ZhangDepartment of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China.
Kunyan ZhouDepartment of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China.
Dan ShanDepartment of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China.
Xiaoyan LuoDepartment of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China.
West China Second University Hospital of Sichuan University · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMedical abortion became an alternative method of pregnancy termination following the development of prostaglandins and antiprogesterone in the 1970s and 1980s. Recently, synthesis inhibitors of oestrogen (such as letrozole) have also been used to enhance efficacy. The most widely researched drugs are prostaglandins (such as misoprostol, which has a strong uterotonic effect), mifepristone, mifepristone with prostaglandins, and letrozole with prostaglandins. More evidence is needed to identify the best dosage, regimen, and route of administration to optimise patient outcomes. This is an update of a review last published in 2011.

objectivesTo compare the effectiveness and side effects of different medical methods for first trimester abortion. SEARCH

methodsWe searched CENTRAL, MEDLINE, Embase, Global Health, and LILACs on 28 February 2021. We also searched Clinicaltrials.gov and the World Health Organization's (WHO) International Clinical Trials Registry Platform, and reference lists of retrieved papers. SELECTION CRITERIA: We considered randomised controlled trials (RCTs) that compared different medical methods for abortion before the 12th week of gestation. The primary outcome is failure to achieve complete abortion. Secondary outcomes are mortality, surgical evacuation, ongoing pregnancy at follow-up, time until passing of conceptus, blood transfusion, side effects and women's dissatisfaction with the method. DATA COLLECTION AND ANALYSIS: Two review authors independently selected and evaluated studies for inclusion, and assessed the risk of bias. We processed data using Review Manager 5 software. We assessed the certainty of the evidence using the GRADE approach. MAIN

resultsWe included 99 studies in the review (58 from the original review and 41 new studies). 1. Combined regimen mifepristone/prostaglandin Mifepristone dose: high-dose (600 mg) compared to low-dose (200 mg) mifepristone probably has similar effectiveness in achieving complete abortion (RR 1.07, 95% CI 0.87 to 1.33; I AUTHORS'

conclusionsSafe and effective medical abortion methods are available. Combined regimens (prostaglandin combined with mifepristone, letrozole, estradiol valerate, tamoxifen, or methotrexate) may be more effective than single agents (prostaglandin alone or mifepristone alone). In the combined regimen, the dose of mifepristone can probably be lowered to 200 mg without significantly decreasing effectiveness. Vaginal misoprostol is probably more effective than oral administration, and may have fewer side effects than sublingual or buccal. Some results are limited by the small numbers of participants on which they are based. Almost all studies were conducted in settings with good access to emergency services, which may limit the generalisability of these results.

Indexed as

Abortifacient Agents, NonsteroidalAbortion, SpontaneousMisoprostolOxytocicsDiarrheaDrug Therapy, CombinationEstradiolFemaleHumansLetrozoleMethotrexateMifepristonePregnancyPregnancy Trimester, FirstProstaglandinsTamoxifenAbortifacient Agents, NonsteroidalEstradiolLetrozoleMethotrexateMifepristoneMisoprostolOxytocicsProstaglandinsTamoxifen

Identifiers

PMID35608608
PMCPMC9128719
OpenAlexW4281387705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.